Abstract
Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to ContraceptionReferences
- Pill kills! The pill. A biography of the drug that changed the world. Random House, New York1995: 301-312
- A placebo-controlled double-blind crossover investigation of the side effects attributed to oral contraceptives.Fertil Steril. 1971; 22: 609-623
- A double-blind comparison of two oral contraceptive vs. containing 50 ��g and 30 ��g ethinyl estradiol.Curr Ther Res. 1974; 16: 281-288
- The pill: 30 years of safety concerns.(Accessed on February 6, 2006)
- The description of menstrual bleeding patterns: towards fewer measures.Stat Med. 1991; 19: 267-284
- A multicenter, randomized study of an extended cycle oral contraceptive.Contraception. 2003; 68: 89-96
- The analysis of vaginal bleeding patterns induced by fertility regulating methods.Contraception. 1986; 34: 253-260
- Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 ��g levonorgestrel and 10 ��g ethinyl estradiol (Alesse��).Am J Obstet Gynecol. 1999; 181: S39-S44
- Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs. an oral contraceptive.JAMA. 2001; 285: 2347-2354
- Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin FE 1/20.Contraception. 2001; 63: 289-295
- An open-label, multicenter, noncomparative safety and efficacy study of Mircette, a low-dose estrogen���progestin oral contraceptive.Am J Obstet Gynecol. 1998; 179: S2-S8
- An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen.Contraception. 2000; 61: 105-111
- Contraceptive efficacy and cycle control with the Ortho Evra���/Evra��� transdermal system: the analysis of pooled data.Fertil Steril. 2002; 77: S13-S18
- Patient compliance with paper and electronic diaries.Control Clin Trials. 2003; 24: 182-199
- Electronic subject diaries in clinical trials.Appl Clin Trials. 2000; : 3-8
- Determinants of menstrual bleeding patterns among women using natural and hormone methods of contraception: I. Regional variation.Contraception. 1988; 38: 227-243
- Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception.Contraception. 1988; 38: 181-206
- The analysis of menstrual bleeding patterns: a review.Contraception. 1988; 38: 129-156
- Bleeding patterns after immediate vs. conventional oral contraceptive initiation: a randomized, controlled trial.Fertil Steril. 2003; 79: 322-329
Mircette�� Medical Review(s). Center for Drug Evaluation and Research Application No. NDA 20-713.
Article info
Publication history
Footnotes
���This is the first of a two-article series describing the outcomes of the Hormonal Contraceptives Trial Methodology Consensus Conference held in Philadelphia, PA, on September 24, 2005, sponsored by the Department of Continuing Education of the University of Southern California Keck School of Medicine and funded by an unrestricted educational grant from Duramed Pharmaceuticals.
������Financial Disclosure: Daniel R. Mishell, Jr., M.D.: research grants from Berlex; advisory board member/consultant to Berlex, Duramed and Ortho McNeil. John Guillebaud, M.D.: research grants (prior to 2002) from Contrel, Organon, Ortho McNeil/Janssen-Cilag, Schering and Wyeth; limited term consultancy for Contrel, Organon, Ortho/Janssen-Cilag, Schering and Wyeth; stockholding: none. Carolyn Westhoff, M.D.: research grants from Duramed and Organon; consultant to Duramed, Berlex, Organon and Schering. Anita L. Nelson, M.D.: research grants from Berlex, Organon and Pfizer; speakers bureau: Duramed, Berlex, FEI Women's Health, Organon, Ortho-McNeil and Pfizer; advisory board member/consultant to Berlex, Church and Dwight and Duramed. Andrew M. Kaunitz, M.D.: clinical trials (funding to University of Florida Research Foundation) from Duramed Pharmaceuticals, Berlex, Johnson and Johnson, National Institutes of Health; speaker and/or consultant to the American College of Obstetricians and Gynecologists, the Association of Reproductive Health Professionals, Duramed Pharmaceuticals, Berlex, Johnson and Johnson, Pfizer, Procter and Gamble; stockholder: Noven, Roche, Sanofi-Aventis and Procter and Gamble. James Trussell, Ph.D.: none. Ann Jeanette Davis, M.D.: honorarium, consulting fees and research support from a variety of pharmaceutical companies, including Ortho, Wyeth, Proctor and Gamble, Duramed and Organon, among others, in addition to support from the National Institutes of Health.
